Q1 Earnings Forecast for VNDA Issued By HC Wainwright

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Stock analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Vanda Pharmaceuticals in a research note issued on Tuesday, February 18th. HC Wainwright analyst R. Selvaraju anticipates that the biopharmaceutical company will earn ($0.08) per share for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($0.35) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals’ Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.10 EPS and Q4 2026 earnings at $0.14 EPS.

Separately, StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They set a “hold” rating on the stock.

Vanda Pharmaceuticals Trading Up 0.9 %

NASDAQ VNDA opened at $4.46 on Wednesday. The firm’s 50 day moving average price is $4.61 and its 200-day moving average price is $4.84. Vanda Pharmaceuticals has a 52-week low of $3.71 and a 52-week high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. The business had revenue of $53.19 million for the quarter, compared to the consensus estimate of $51.00 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quantinno Capital Management LP purchased a new position in shares of Vanda Pharmaceuticals in the fourth quarter worth $48,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Vanda Pharmaceuticals by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 4,374 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Vanda Pharmaceuticals during the fourth quarter worth $69,000. Zacks Investment Management purchased a new position in shares of Vanda Pharmaceuticals during the fourth quarter worth $74,000. Finally, Intech Investment Management LLC purchased a new position in shares of Vanda Pharmaceuticals during the third quarter worth $84,000. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.